COVID-19: Clearer picture of long COVID slowly emerging

The first long COVID study conducted in South Africa found that 82% of patients still had persistent or new symptoms a month after their discharge from hospital. However, much is still unknown about what exactly causes this and how to alleviate the suffering, which is becoming an increasing health burden across the globe. Elsabé Brits surveyed the latest evidence and asked local experts to place it in context.

Read More

COVID-19 in kids: What have we learnt one year later?

It has been over a year since the world saw the first confirmed case of COVID-19, yet the science behind the virus’ physical impact on children remains relatively unclear. Kathryn Cleary spoke to two experts in paediatrics and immunology to get an update on what we have learnt so far.

Read More

Why broadly neutralising antibodies might be the next big thing in HIV

We know antiretroviral therapy can prevent HIV infection, but can natural biological substances do the same? The results of a recent scientific trial have answered this question: Yes, using broadly neutralising antibodies. But what are broadly neutralising antibodies? How do they work? And when will the average person get access to them? Amy Green breaks down the science.

Read More

Where are we in the race for a HIV vaccine?

While progress in the race for effective COVID-19 vaccines has been rapid and impressive, an effective HIV vaccine remains elusive. As part of Spotlight’s World AIDS Day 2020 coverage, Kathryn Cleary asks two of South Africa’s top vaccine researchers to update us on where we are in the race for an HIV vaccine.

Read More